Browsing by Author "Castaneda-Altamirano, CA"

Now showing 1 - 3 of 3

Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women
(American Association for Cancer Research Inc., 2022) Zavala Valentin, A; Casavilca-Zambrano, S; Navarro-Vásquez, J; Castaneda-Altamirano, CA; Valencia, G; Morante, Z; Calderón, M; Abugattas-Saba, JE; Gómez-Moreno, HL; Fuentes-Rivera, HA; Liendo-Picoaga, R; Cotrina-Concha, JM; Monge, C; Neciosup, SP; Scott, H; Hu, D; Sánchez, SE; Williams, A; Núñez-Marrero, A; Godoy, L; Hechmer, A; Olshen, AB; Dutil, J; Ziv, E; Zabalet,a J; Gelaye B; Vásquez, J; Gálvez-Nino, M; Enriquez-Vera, D; Vidaurre, T; Fejerman, L
Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/ Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53
Association between PIK3CA Mutations in Blood and Tumor-Infiltrating Lymphocytes in Peruvian Breast Cancer Patients
(Asian Pacific Organization for Cancer Prevention, 2022) Castaneda-Altamirano, CA; Castillo-García, M; Bernabe, LA; Suarez, N; Romero, A; Sanchez, J; Torres, E; Enciso, J; Tello, K; Enciso, N; Velarde, M; De La Cruz-Sacasqui, M; Dunstan Yataco, J; Cotrina-Concha, JM; Abugattas-Saba, JE; Pinillos-Portella, MA; Roque, K; Fuentes-Rivera, Hugo; Poquioma-Rojas, E; Guerra, H; Gomez-Moreno, HL
Objective: To evaluate the relationship between circulating tumor DNA (ctDNA) presence and tumor features including tumor-infiltrating lymphocyte (TIL) levels in Peruvian breast cancer patients. Materials and Methods: This was a prospective study conducted at the Instituto Nacional de Enfemedades Neoplasicas, Peru. We evaluated level of TIL and PIK3CA mutations in ctDNA. Clinical characteristics, including outcome data, were collected from the patient file. Survival was calculated from the date of blood sample drawn to the event time. Data collected were analyzed using SPSS software version 25. Results: We analyzed plasma samples from 183 breast cancer patients. most cases were of Luminal-B (44.8%) phenotype and stage II (41.5%), and median stromal TIL was 30%. PIK3CA mutation in ctDNA was detected in 35% cases (most with E545K) and was associated with lower TIL level (p=0.04). PIK3CA in ctDNA tended to be associated with advanced stages (p=0.09) in the whole series and with higher recurrence rates (p=0.053) in the non-metastatic setting. Patients with presence of PIK3CA in ctDNA tended to have shorter survival (p=0.083). Conclusion: Presence of PIK3CA mutation in ctDNA was frequently found in our Peruvian breast cancer series, was associated with lower TIL levels and tended to predict poor outcomes. © This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.
Molecular and Cellular Analyses of Breast Cancers in Real Life
(Springer, 2022) Castaneda-Altamirano, CA
Breast cancer is the most common women’s malignancy. Incorporation of biomarkers of prognosis and prediction of response are needed to improve treatment management. Lectures for immunohistochemistry of estrogen, progesterone, and HER2 receptors as well as Ki67 staining in cancer cells have been incorporated, and their positive cutoffs have periodically been reviewed. Gene expression platforms in tumor lesions as well as germline and somatic mutations have also been included in the practice for treatment selection. Liquid biopsy evaluating circulating tumor cells (CTCs) and circulating DNA can also predict survival and has reached the clinical practice, although it needs better standardization. On the other side, biomarkers can also evaluate stroma cells in the tumor microenvironment, and they can predict survival and response to chemotherapy and targeted treatment. They have been incorporated in the daily practice, and new methodologies for obtaining more information are currently being developed.